Mineralocorticoid receptor antagonists in patients with chronic kidney disease

Volume: 219, Pages: 107701 - 107701
Published: Mar 1, 2021
Abstract
Mineralocorticoid receptor antagonists (MRA) can reduce cardiovascular morbidity and mortality in patients with heart failure and ischemic heart disease. In addition, these agents have been used in patients with diabetic nephropathy to control proteinuria and slow down chronic kidney disease (CKD) progression. Current guidelines recommend against the use of MRAs in patients with advanced CKD. However, there is growing interest on their use in...
Paper Details
Title
Mineralocorticoid receptor antagonists in patients with chronic kidney disease
Published Date
Mar 1, 2021
Journal
Volume
219
Pages
107701 - 107701
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.